MyoKardia Inc logo

MYOK - MyoKardia Inc News Story

$224.91 0.0  0.0%

Last Trade - 16/11/20

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 6853

MyoKardia Announces Awardees of the Second Annual MyoSeeds™ Research Grants Program

Wed 4th November, 2020 1:30pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201104:nGNX8gN1yT


BRISBANE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:
MYOK) today announced three awardees of the 2020 MyoSeeds™ Research Grant
Program, who have been selected to receive $250,000 each in support of
original, independent research in the biology and underlying mechanisms of
cardiomyopathies. The MyoSeeds Program was founded to help advance
MyoKardia’s mission to promote understanding and treatment of the underlying
drivers of serious cardiovascular diseases. 

More than 50 applicants submitted proposals, which were assessed for
scientific merit, feasibility and impact of the proposed project, and
alignment with the research priorities for the funding cycle. This year’s
MyoSeeds awardees join a growing community of industry, academic and clinical
researchers striving to shed new light on the underlying drivers of heart
disease:
* Ju Chen, PhD, Professor, University of California, San Diego 
Topic: Protective Role of BAG3 in Heart Failure
Dr. Chen's goal is to understand why the human BAG3 C151R variant is
protective for DCM-induced heart failure. BAG3 is a cardiac co-chaperone
protein essential for maintaining protein homeostasis and normal cardiac
function. Mutations in BAG3 can result in dilated cardiomyopathy (DCM), and
downregulation of BAG3 is associated with heart failure.
* Da-Zhi Wang, PhD, Professor, Boston Children’s Hospital, Boston 
Topic: AAV-based Strategies to Define the Function of Long Non-Coding RNAs in
the Heart
Dr. Wang's project is designed to investigate novel cardiac-expressed long
noncoding RNAs (lncRNAs) to provide novel molecular information about the
genetic controls underlying cardiomyopathy. The majority of the human genome
is actively transcribed to produce large numbers of non-coding transcripts,
including lncRNAs.
* Jorge Alegre-Cebollada, PhD, Assistant Professor, Spanish National Center
for Cardiology Research, Madrid, Spain 
Topic: Titin Allelic Discrimination to Uncover Pathophysiology Mechanisms in
dilated cardiomyopathy (DCM)
Dr. Alegre-Cebollada's lab is developing a new technology to investigate the
interaction between normal and disease-causing titin alleles in cellular
models of DCM. Using a fluorescent-based technology, they aim to quantify how
much of each titin variant is produced and degraded and localized in the cell.
This will uncover if DCM alleles lead to changes in titin levels, altered
rates of production/degradation of titin, and/or defective titin localization
“We started the MyoSeed Research Grants Program in 2018 with the goal of
supporting independent research to help further the understanding of the
underlying biology and mechanism of cardiomyopathies and of broader heart
failure. The scientific insights that have emerged from the program are doing
just that and we are excited by the contributions to come from this new class
of awardees,” said Robert McDowell, PhD., MyoKardia’s Chief Scientific
Officer. “We congratulate our MyoSeeds fellows on their successful proposals
and thank all of the applicants for their participation and interest in
advancing the research of cardiovascular diseases.”

About the MyoSeeds™ Research Grants Program
The MyoSeeds™ Research Grants Program (MyoSeeds™) is intended to support
original, independent research in the biology and underlying mechanisms of
cardiomyopathies, as part of MyoKardia’s mission to change the world for
people with serious cardiovascular diseases. The program supports original
research into the biology and underlying mechanisms of cardiomyopathies and is
part of our ongoing commitment to bring precision cardiovascular medicine and
novel therapies to patients. MyoKardia is committed to furthering
collaborative efforts that bring together researchers, the medical community,
drug developers, and the patients whom we all serve. 

About MyoKardia
MyoKardia is a clinical-stage biopharmaceutical company discovering and
developing targeted therapies for the treatment of serious cardiovascular
diseases. The company is pioneering a precision medicine approach to its
discovery and development efforts by 1) understanding the biomechanical
underpinnings of disease; 2) targeting the proteins that modulate a given
condition; 3) identifying patient populations with shared disease
characteristics; and 4) applying learnings from research and clinical studies
to inform and guide pipeline growth and product advancement. MyoKardia’s
initial focus is on small molecule therapeutics aimed at the proteins of the
heart that modulate cardiac muscle contraction to address diseases driven by
excessive contraction, impaired relaxation, or insufficient contraction. Among
its discoveries are three clinical-stage therapeutics: mavacamten (formerly
MYK-461); danicamtiv (formerly MYK-491) and MYK-224.

MyoKardia’s mission is to change the world for people with serious
cardiovascular disease through bold and innovative science.

Contacts 
Michelle Corral 
Executive Director, Corporate Communications and Investor Relations 
MyoKardia, Inc. 
650-351-4690 
ir@myokardia.com

Hannah Deresiewicz (investors) 
Stern Investor Relations, Inc. 
212-362-1200 
hannah.deresiewicz@sternir.com

Julie Normant (media)
W2O
628-213-3754
jnormart@w2ogroup.com


(https://www.globenewswire.com/NewsRoom/AttachmentNg/f2c7a5a7-d19b-4226-80bb-31c050a253fa)



GlobeNewswire, Inc. 2020
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.